Japanese Drugmaker Eisai Handed 483 Due to Data Integrity, Quality Concerns

Drug Industry Daily
The FDA served drug manufacturer Japanese drugmaker Eisai a Form 483 after an inspection of its Baltimore, Maryland facility revealed recordkeeping and quality control issues that led to incomplete data and unrestricted access to computers.

To View This Article:


Subscribe To Drug Industry Daily